ABSTRACT
SUMMARY

What is already known about this subject
• NSAID sulindac prevents tumours in many animal models of colorectal cancer and has also shown some promise in clinical trials.
• Long-term use of some NSAIDs is associated with significant gastrointestinal side effects.
• There are conflicting reports on the efficacy of sulindac in ApcMin mice, raising questions as to whether certain germline or somatic gene defects reduce the efficiency of chemoprevention or increase the side effects.
What are the new findings
• We show that sulindac prevented carcinogenesis in the distal colon of wild type and p53 or mismatch repair deficient mice.
• However sulindac induced new inflammatory lesions in the mouse proximal colon, which progressed to malignancy more frequently in p53 or mismatch repair deficient mice.
• The premalignant changes started from mild surface damage in the colon epithelium, which progressed to chronic inflammation if the sulindac diet was maintained.
• This region in the proximal colon was characterised by a distinct profile of pro-and anti-inflammatory factors, which were differentially modulated by the sulindac diet, including upregulation of MIP-2 and Hif1α.
• Sulindac has both beneficial and harmful effects in vivo, which are associated with different microenvironments within the colon.
How might it impact on clinical practice in the foreseeable future
• It is unlikely that sulindac use in humans leads to as serious side effects as in the genetically modified Msh2 or p53 deficient mice.
INTRODUCTION
The great potential of non-steroidal anti-inflammatory drugs (NSAIDs) in cancer chemoprevention has been recognised for decades. [1] For example, in a recent clinical trial of aspirin in the Lynch syndrome, there was a long term reduction in the incidence of colorectal carcinoma after the trial had been concluded. [2, 3] Lynch syndrome patients are carriers of DNA mismatch repair (MMR) gene mutations and have a high risk of developing recurrent tumours. The data on sulindac in the Lynch syndrome are limited, but short-term administration of sulindac increased epithelial cell proliferation in the proximal colon of MMR mutation carriers, raising concerns about its potential chemopreventive effect. [4] The NSAIDs celecoxib and rofecoxib reduced the risk of sporadic colorectal adenomas in clinical trials, but were associated with serious side effects, including cardiovascular problems or gastrointestinal ulcers, bleeding and obstructions. [5, 6] Subsequently, rofecoxib was withdrawn from clinical use in arthritis but other NSAIDs are among the most commonly used medicines.
It is now widely recognised that apart from gastroduodenal toxicity, NSAIDs also have significant side effects in the colon, such as non-specific, eosinophilic or ischemic colitis, ulcers, strictures and exacerbation of colonic diverticular disease. [7] This implies that NSAIDs can have diametrically opposed effects on the colon, chemoprevention of tumours on the one hand and induction or exacerbation of inflammation on the other. Chronic inflammation can lead to carcinogenesis, as is well known in chronic colitis and the dextran sodium sulfate mouse model of this disease. [8, 9] The mechanism of NSAID chemoprevention and the cause of the side effects in vivo remain unclear. NSAIDs are highly effective in preventing tumour development in some animal models, such as the azoxymethane (AOM) model of colorectal cancer in rats and in
p53
∆/+ or p53 ∆/∆ mice. [10, 11] Dietary sulindac also caused a significant decrease in the number of polyps in ApcMin mice. [12] However, a subsequent study reported a decrease of tumour development in the small intestine of ApcMin mice but an increase of incidence, multiplicity and volume of tumours in the colon, especially in the caecum, with a sulindac diet. [13] In the Apc ∆/+ Msh2 ∆/∆ mice no difference was observed in the numbers of polyps or aberrant crypt foci (ACF) in the colon between mice receiving control diet, sulindac or a specific COX-2 inhibitor, MF-tricyclic. [14] Therefore, we wanted to determine whether genetic defects that are found in 
MATERIALS AND METHODS
Mouse lines
HIF1α
F/F were crossed with VILcre mice (B6.SJL-Tg(vil-cre)997Gum/J; Jackson Laboratories, Bar Harbor, Maine) [16, 17] longitudinally and all distal tumours and proximal lesions, which were visible under a dissecting microscope, were counted and measured. The total surface area of tumours or lesions per mouse was determined as previously described. [21] A subset of colons were stained with 0.2% methylene blue for 4 min for the measurement of tumour/lesion dimensions.
Histopathology analysis
All visible lesions and tumours from each colon were biopsied for histopathology analysis together with biopsies of macroscopically normal tissue. The entire length of the biopsies was examined equivalent to 7-14 high power fields. The severity of inflammation was assessed over the entire area that was inflamed. All specimens, including untreated controls, were analysed by an anatomical pathologist (JED). Assessment was conducted using blinded slides, and findings were peer-reviewed by a second pathologist for concordance.
The features assessed included: acute and/or chronic inflammation, lymphoid aggregates, hyperplastic and /or degenerative changes of the surface epithelium, architectural distortion, fibrosis, and neoplasia, classified as epithelial dysplasia or adenocarcinoma.
Dysplasia was graded as negative, indefinite for low-grade dysplasia, low-grade and highgrade dysplasia according to the Riddell classification. [22] Only biopsies that show convincing neoplastic glands within a desmoplastic stroma extending beyond the muscularis mucosae were regarded as invasive adenocarcinoma. Some proximal colon biopsies with severe inflammation showed bland appearing displaced glands extending through the muscularis mucosae, which on occasion even showed some mucin distension associated with these glands. These were regarded as pseudoinvasion or lesions of colitis cystica profunda.
Ulceration was defined as loss of the colonic mucosa associated with an acute inflammatory reaction extending at least through the muscularis mucosae. An erosion was 
Measurement of drug concentration in colon mucosa
Colon mucosa was lightly scraped and snap frozen, then weighed and homogenised in liquid nitrogen. Sulindac and its metabolites, sulindac sulfone and sulindac sulfide, were extracted as previously described [25] and analysed with a Thermo Scientific Quantum Access triple quadrupole mass spectrometer coupled to a Thermo Scientific Accela UHPLC system (Thermo Fisher Scientific, Waltham, MA). Quantitation was performed using external calibration curves, corrected using the internal standard, piroxicam, 1ng/µl.
Statistical analysis
Gene/protein expression and sulindac metabolites in tissue were compared using t-tests, and the overall frequencies of neoplasia with Fisher's Exact Test. Severity of inflammation, numbers of apoptotic cells/crypt column, number/size of tumours or lesions and Bax/BclxL, Bax/Bcl2 ratios were compared using the Wilcoxon Mann Whitney test (StatXact 8, Cytel
Software Corporation, Cambridge, MA). We then carried out a systematic pathology comparison between the lesions and tumours in the proximal and distal colon and the surrounding uninvolved mucosa (supplementary tables 2-3). Hyperplastic changes were more common in the proximal lesions (up to 100%) than in the distal tumours (up to 25%). Mucinous adenocarcinomas and tissue ulceration were only found in the proximal colon. Tissue damage (erosion and ulceration) was more frequent in the lesions than surrounding uninvolved tissue in all genotype groups (p<0.0001) but was also found in the surrounding mucosa.
RESULTS
Sulindac prevents carcinogenesis in the distal
Sulindac metabolites accumulate in the colon mucosa.
Much of the water absorption from the bolus occurs at the mucosal folds in the proximal colon where the faecal material is still in semi-liquid form, while the faeces are solid in the distal colon. To test whether sulindac contained in the semi-liquid bolus causes a higher accumulation of drug in the proximal colon, we measured the concentrations of sulindac and its two metabolites, sulfide and sulfone in the mucosal lining. Sulindac concentration was low ( fig 2F) , whereas its derivatives accumulated at higher concentrations than the pro-drug. Sulfone and sulfide concentrations were marginally higher in the proximal colon than in the distal colon, but this was not statistically significant.
Premalignant proximal lesions develop in a defined region of the proximal colon.
We 3A) . We next assessed pro-and anti-apoptotic markers Bax, Bcl-xL and Bcl-2 by western blot and qPCR analysis and determined the ratio of Bax/Bcl-xL and Bax/Bcl2, which can indicate changes in the sensitivity of cells to apoptosis.
These ratios remained similar in the mice treated with sulindac compared to control mice, with minor increases in the proximal colon (supplementary fig 2) . Thus we did not observe a decrease but a slight increase of apoptosis, which may be explained by increased inflammation as previously reported in ulcerative and experimental colitis. [26, 27] We also examined p21, which mediates the chemopreventive effect of sulindac in Apc1638+/-mice.
[28] p21 expression was not significantly changed in the P2 region, but there was a small but significant increase in the distal colon ( fig 3B) .
Sulindac modulates expression of pro-inflammatory genes in the colon.
As colon neoplasia was clearly associated with the inflammatory lesions in sulindac fed mice, we next examined a panel of pro-and anti-inflammatory factors, which have been previously implicated in mouse models of colon inflammation, such as HIF1α and NFκB target genes. Constitutive expression of HIF1α augments inflammation in experimental colitis [29] and the NFκB pathway links inflammation and cancer in the AOM/DSS model of colitis. [9] We detected strong upregulation of HIF1α by sulindac in the lesions and in the uninvolved mucosa at the P2 region ( fig 4A) . Of the NFκB target genes, [9, 29] the most striking effect was seen for MIP-2, IL1β and COX-2, which were very strongly upregulated by the sulindac diet in the lesions ( fig 4A) . A20 an anti-inflammatory and anti-apoptotic factor, [30] was slightly downregulated in the P2 region, but the expression of other NFkB target genes IL6, TNFα and ICAM was variable and they were not strongly upregulated by the sulindac diet ( fig 4A) . We also examined PECAM, which mediates transendothelial leukocyte migration in experimental colitis, [31] and found that it was slightly upregulated in the lesions. iNOS was upregulated by the sulindac diet only in the distal colon.
As we observed strong MIP-2 upregulation in the mucosal lining throughout the colon in sulindac-treated mice, we next tested whether sulindac has the same effect in vitro independent of inflammatory cells. MIP-2 is the mouse homolog of IL8, a chemokine that is overexpressed in many solid cancers and causes recruitment of infiltrating neutrophils to the tumour microenvironment. [32] We treated the COX-2 deficient human colon cancer cell line HCT15 with sulindac sulfide. This treatment resulted in nearly 40-fold upregulation of IL8 but only 2-3 fold upregulation of TNFα and ICAM and had no effect on IL6 expression ( fig   4B) . TNFα treatment of HCT15 cells was used as a positive control to demonstrate strong upregulation of IL8, ICAM and TNFα upon cytokine stimulation.
[33] Therefore, we conclude that the sulindac diet can differentially modulate the expression of pro-inflammatory genes in the proximal and distal colon mucosa and that the sulindac-induced lesions have the highest expression of pro-inflammatory factors.
Sulindac diet induces HIF1α overexpression in the site susceptible to lesions.
HIF1α is a transcription factor that regulates many aspects of cancer biology but can also function as a barrier protective factor in the colon. [18, 34] HIF1α protein is rapidly degraded unless it is stabilised by pro-inflammatory cytokines or hypoxic conditions. Therefore, we next investigated if HIF1α protein was expressed in the lesions apart from its transcriptional upregulation. There was an increase of nuclear HIF1α protein expression in the lesions compared with the surrounding mucosa and the distal colon ( fig 5A) . The pattern of HIF1α overexpression was confined to the surface epithelium of sulindac-induced lesions.
However, this overexpression was not accompanied by upregulation of the Hif1α responsive genes CD73 and ITF, which are important mediators of epithelial barrier protection. For CD73, there was a gradient of increasing expression from proximal to the distal colon, where CD73 was expressed more than 100-fold higher than in the P1 region ( fig 5B) . ITF also showed higher expression in the distal colon compared to the proximal colon.
Mucosal damage was profound in the lesions and resulted in crypt elongation and increased cell proliferation as assessed by immunohistochemistry for the proliferation marker Ki67 compared to normal mucosa ( fig 5C,E) . Ki67 positive cells were found at the epithelium surface in the lesions, while in normal conditions they were confined to the proliferative zone of the crypt base. Many of the cells that were positive for HIF1α also stained positive for Ki67 (fig 5D arrows) . We conclude that HIF1α is upregulated by the sulindac diet in the P2 region and that the HIF1α protein is stabilised in epithelial cells that have proliferative potential.
Next we investigated if HIF1α protein expression at the site of the lesions was associated with hypoxia, as it has been suggested that NSAID-induced tissue ulceration observed in some patients is caused by reduced blood supply to the site of damage. [35] We used pimonidazole, a previously validated hypoxia marker and detected positive staining in the region of the mucosal folds, but also in the rectum and intermittently in other regions (supplementary fig 3) . Similar pattern of hypoxia staining was seen in both sulindac fed and control mice. Since any variation in tissue collection or fixation can affect the staining intensity between different mice, it cannot be determined if sulindac increased hypoxia.
However, it can be concluded that the site of the lesions was prone to hypoxia, but this was not the only region affected.
Hif1α expression is pro-inflammatory in the proximal colon lesions.
To determine whether HIF1α has a pro-inflammatory rather than protective function in the proximal colon, we analysed mice deficient for HIF1α in the intestinal epithelial cells 
DISCUSSION
This study was designed to determine if sulindac chemoprevention was affected by genetic defects that are important in colorectal cancer, such as p53 deficiency or the MMR defect. We have shown that sulindac was as effective in preventing AOM-induced distal colon tumours on the background of Msh2 or p53 deficiency as in the WT mice. However, the sulindac treatment also caused side effects in the proximal colon, which were more pronounced in mice with Msh2 or p53 deficiency. These results are in agreement with a recent report of intestinal and proximal colon carcinogenesis in response to sulindac, in mice heterozygous for a mutant Apc or the MMR gene Mlh1. [36] It was striking that the sulindac-induced lesions were confined to a specific region (P2) of the proximal colon. Small lesions with inflammatory cell infiltration became visible after just one week of sulindac diet. These early lesions showed surface crypt and epithelium damage suggesting initial mucosal irritation by sulindac. This region may be more susceptible to mechanical surface irritation because most water absorption from the bolus is completed at the mucosal folds. Although the lesions progressed to neoplasia more frequently in mice with Msh2 or p53 deficiency, the macroscopic lesions developed to a similar extent in all mice, including the WT. Therefore, the initial insult to the mucosa was similar in all mice, suggesting that these early lesions were premalignant regardless of the genetic background. Our model does not single out a specific gene that is responsible for the early tissue inflammation in the P2 region, but has identified a combination of factors that characterised its unique response to the sulindac diet.
A number of genes were differentially expressed between different parts of the colon or further regulated by the sulindac diet in the P2 region, including upregulation of HIF1α , is overexpressed in many solid cancers, where it causes recruitment of infiltrating neutrophils to the tumour microenvironment, and promotes proliferation of human colon cancer cells in vitro. [32, 37] MIP-2 also increases neutrophil and lymphocyte recruitment in the mouse intestine and increases inflammation in the DSS model of colitis. [38, 39] The active role of epithelial cells as modulators of the inflammatory process is now well accepted. In addition,
we observed upregulation of PECAM in the lesions. PECAM is a cell adhesion factor involved in leukocyte migration, and promotes migration of blood monocytes to tissue, particularly at sites of inflammation, where they maturate to tissue macrophages. [31, 40] It is unclear if PECAM is a tumour promoter but it is expressed in colorectal cancer cells. [41] Thus upregulation of both MIP-2 and PECAM is associated with the presence of infiltrating inflammatory cells in the lesions of the P2 region.
Pro-inflammatory factors IL1β and COX-2 were also upregulated in the lesions. It is now well accepted that IL1β is a tumour promoter [42] and that COX-2, which is overexpressed in colorectal cancer, plays a key role in intestinal polyp formation. [43] It was unexpected that there was a slight increase of apoptosis in the lesions, as apoptosis is a chemopreventive mechanism linked to sulindac. Also, sulindac-induced tumorigenesis was previously shown to be associated with decreased apoptosis in ApcMin mice [13] . As we did not compare the effect of sulindac on apoptosis in all genetic backgrounds, the significance of this is unclear. However, these results are consistent with the findings in ulcerative colitis, as well as in DSS-induced colitis, where increased epithelial cell proliferation is associated with increased apoptosis. [26, 27] We also observed slight downregulation of A20 in the lesions, which is consistent with its role as a major anti-apoptotic and anti-inflammatory protein in a mouse model of experimental colitis.
[30] Interestingly, we did not observe a change in p21 levels with sulindac in the proximal colon, whereas there was significant upregulation of p21 in the distal colon. The chemopreventive effect of sulindac in APC1638 +/-mice is abolished with targeted inactivation of p21. [28] Therefore, our results are consistent with the role of p21-mediated chemoprevention by sulindac in the distal colon.
A striking aspect of the proximal lesions in our study was upregulation of HIF1α by the sulindac diet in the P2 region and protein overexpression of HIF1α in proliferating epithelial cells expressing Ki67. HIF1α is a transcription factor that activates many genes involved in cancer biology, including angiogenesis, cell proliferation/survival, glucose metabolism and invasion. [34] Increased HIF1α signalling in the intestinal epithelial cells leads to a hyperinflammatory reaction in the mouse colon and its overexpression is a feature of serrated colon adenocarcinomas in humans. [29, 44] HIF1α is degraded in normoxic conditions unless stabilised by pro-inflammatory cytokines, such as IL1β through the NFkB pathway. The HIF1α pathway has been described as a link between inflammation and cancer [45, 46] but the HIF1α ∆/∆IEC mice used here were not informative regarding the role of HIF1α in cancer. The reduction of colon inflammation in these mice suggests that HIF1α has a pro-inflammatory function in the sulindac model of proximal carcinogenesis. This was consistent with our observation that the HIF1α responsive genes ITF and CD73 that have been implicated in barrier protection, [47, 48] were unaffected by the sulindac diet.
NFκB activated genes, in particular IL6, are important in chronic colitis associated cancer.
[9] Here we could not show strong upregulation of IL6, TNFα or ICAM by sulindac, but other NFκB targets MIP-2, IL1, and COX-2 were upregulated in the proximal lesions.
Therefore, it appears that colon carcinogenesis in sulindac-induced lesions is associated with a different profile of NFκB target gene expression compared to the AOM/DSS model of colitis. [9] However, the role of NFκB activation in the colon carcinogenesis in this model can 
